SCHEMBL12267198

SCHEMBL12267198

CC(CCl)COc1ccc(C(C)(C)c2ccc(OCC(O)CCl)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 2/20 0.76
▸ HTT P42858 3/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ KMT2A Q03164 3/20 0.48
▸ MAPT P10636 4/20 0.45
▸ GAA P10253 1/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ MEN1 O00255 2/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39
▸ PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6131219 0.92 AR (0.88) ARHTTHIF1AKMT2AMAPT
SCHEMBL12515785 0.92 AR (0.88) ARHTTHIF1AKMT2AMAPT
SCHEMBL16232995 0.92 AR (0.72) ARHTTHIF1AKMT2AMAPT
SCHEMBL16232994 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL15257210 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL13826212 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL12267221 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL14707520 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL14707519 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT
SCHEMBL14707517 0.92 AR (0.82) ARHTTHIF1AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9862667-B2 Diglycidic ether derivative therapeutics and methods for their use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-01-09 — — US disclosed
US-20170121261-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNITED STATES GOVERNMENT 2017-05-04 — — US disclosed
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-09-19 — — US disclosed
US-20110230556-A1 Diglycidic Ether Derivative Therapeutics and Methods for Their Use THE UNITED STATES GOVERNMENT 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121261-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE UGCG, PTGFR, KLK3 AR 206/4885HTT 4813/4885HIF1A 530/4885
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE MAN2B2, UGCG, KLK3 AR 179/4885HTT 4659/4885HIF1A 1235/4885
US-20110230556-A1 Diglycidic Ether Derivative Therapeutics and Methods for Their Use MAN2B2, KLK3, UGCG AR 125/4885HTT 4653/4885HIF1A 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback